Compare · ABBV vs LCI
ABBV vs LCI
Side-by-side comparison of AbbVie Inc. (ABBV) and Lannett Co Inc (LCI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and LCI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $443.36B, about 7060.9x LCI ($62.8M).
- ABBV has been more active in the news (10 items in the past 4 weeks vs 4 for LCI).
- ABBV has more recent analyst coverage (25 ratings vs 1 for LCI).
- Company
- AbbVie Inc.
- Lannett Co Inc
- Price
- $250.88-2.57%
- $0.72+9.02%
- Market cap
- $443.36B
- $62.8M
- 1M return
- -0.08%
- -
- 1Y return
- +28.51%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2012
- News (4w)
- 10
- 4
- Recent ratings
- 25
- 1
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Lannett Co Inc
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's primary products include Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants, as well as cocaine hydrochloride solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, HEC Group of companies, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was founded in 1942 and is headquartered in Philadelphia, Pennsylvania.
Latest ABBV
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Reports Second-Quarter 2026 Financial Results
- JUVÉDERM® Day Returns to U.S. on August 19
- AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo
- AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
- Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
- SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
Latest LCI
- FDA Approval for METHADONE HYDROCHLORIDE issued to LANNETT CO INC
- FDA Approval for METHADONE HYDROCHLORIDE issued to LANNETT CO INC
- FDA Approval for METHADONE HYDROCHLORIDE issued to LANNETT CO INC
- FDA Approval for METHADONE HYDROCHLORIDE issued to LANNETT CO INC
- FDA Approval for HYDROCODONE BITARTRATE AND ACETAMINOPHEN issued to LANNETT CO INC
- FDA Approval for OXYCODONE AND ACETAMINOPHEN issued to LANNETT CO INC
- FDA Approval for HYDROCODONE BITARTRATE AND ACETAMINOPHEN issued to LANNETT CO INC
- FDA Approval for OXYCODONE HYDROCHLORIDE issued to LANNETT CO INC
- FDA Approval for CODEINE SULFATE issued to LANNETT CO INC
- FDA Approval for LEVOFLOXACIN issued to LANNETT CO INC